RetatrutidStudienlage & Dosis

Top-Studien zu Retatrutid

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

1. 01

   Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

   Lancet (London, England)·2005200 einflussreiche Zitationen

   <h4>Background</h4>In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB1 blocker, on…

2. 02

   Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

   The New England journal of medicine·2005200 einflussreiche Zitationen

   <h4>Background</h4>Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients. The Rimonabant in Obesity-Lipids (RIO-Lipids) study examined…

3. 03

   Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

   Hypertension (Dallas, Tex. : 1979)·2004200 einflussreiche Zitationen

   The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood pressure. In humans, mutations in the peroxisome…

4. 04

   Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

   Lancet (London, England)·2023·n=281200 einflussreiche Zitationen

   BACKGROUND According to current consensus guidelines for type 2 diabetes management, bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single peptide with agonist activity at the glucose-dependent…

5. 05

   Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

   Nature medicine·2024200 einflussreiche Zitationen

   Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8…

6. 06

   The role of incretins in glucose homeostasis and diabetes treatment.

   Pharmacological reviews·2008166 einflussreiche Zitationen

   Incretins are gut hormones that are secreted from enteroendocrine cells into the blood within minutes after eating. One of their many physiological roles is to regulate the amount of insulin that is secreted after eating. In this manner,…

7. 07

   Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

   BMJ (Clinical research ed.)·2007·n=6.365151 einflussreiche Zitationen

   <h4>Objective</h4>To summarise the long term efficacy of anti-obesity drugs in reducing weight and improving health status.<h4>Design</h4>Updated meta-analysis of randomised trials.<h4>Data sources</h4>Medline, Embase, the Cochrane…

8. 08

   Incretin-based therapies for type 2 diabetes mellitus.

   Nature reviews. Endocrinology·2009142 einflussreiche Zitationen

   Incretin-based drugs, such as glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors, are now routinely used to treat type 2 diabetes mellitus. These agents regulate glucose metabolism through multiple mechanisms,…

9. 09

   Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

   Diabetes, obesity &amp; metabolism·2016135 einflussreiche Zitationen

   Over the last few years, incretin‐based therapies have emerged as important agents in the treatment of type 2 diabetes ( T2D ). These agents exert their effect via the incretin system, specifically targeting the receptor for the incretin…

10. 10

    Anti-Obesity Drugs: A Review about Their Effects and Safety.

    Diabetes &amp; metabolism journal·2012·n=15.686131 einflussreiche Zitationen

    The current recommendations for the treatment of obese people include increased physical activity and reduced calories intake. When the behavioral approach is not sufficient, a pharmacologic treatment is recommended. In past years,…